Xiidra is a prescription eye drop FDA-approved in July 2016 to treat dry eye disease in adults and adolescents 17 years and older. Its active ingredient, lifitegrast, belongs to the LFA-1 antagonist drug class. It’s made by Bausch + Lomb.
Xiidra works by blocking LFA-1 proteins on immune T-cells, stopping the inflammatory cycle that drives chronic dry eye. It reduces both symptoms patients feel and signs doctors observe. Clinical trials show improvement at 2 weeks in some patients and at 12 weeks across all 4 studies. The most common side effects are eye irritation, a bad taste, and temporary blurry vision.
This review covers how Xiidra works, what real patients report, how it compares to Restasis, and whether the cost is justified. The data on both sides is here to help patients decide.
What Is Xiidra?
Xiidra is a prescription eye drop FDA-approved in July 2016 to treat the signs and symptoms of dry eye disease in adults and adolescents 17 years and older. Manufactured by Bausch + Lomb, its active ingredient is lifitegrast, one of the few molecules that targets the underlying inflammation driving chronic dry eye.
Here’s the thing: Bausch + Lomb developed Xiidra as an LFA-1 antagonist, which sets it apart from cyclosporine-based alternatives like Restasis and Cequa. The LFA-1 class hits a specific immune pathway that other dry eye drops completely miss.
Each dose comes in a sterile, preservative-free single-use vial containing 0.2 mL of 5% lifitegrast solution. The single-use format ensures sterility and delivers the correct amount of medication for both eyes at each application.
What Does Xiidra Treat?
Xiidra treats the signs and symptoms of dry eye disease, including eye itching, sandy or gritty sensations, redness, and blurry vision caused by insufficient tear production or excessive tear evaporation. It addresses both what patients feel and what doctors can observe.
In fact, Xiidra is specifically designed for patients with persistent dry eye who haven’t found adequate relief from over-the-counter artificial tears, particularly those with inflammatory dry eye disease. Standard lubricating drops can’t address the immune-driven component of chronic dry eye.
Symptoms Xiidra Targets:
- Eye itching and gritty sensations
- Redness and irritation
- Blurry vision from inadequate tear film
- Burning and dryness that interfere with daily activities
- End-of-day discomfort for contact lens wearers
Is Xiidra a Prescription Eye Drop?
Yes. Xiidra is available only by prescription from a healthcare provider and is not sold over the counter; patients must be evaluated by an eye doctor to determine if it’s appropriate for their condition. There’s no self-service option here.
Bottom line: Xiidra is a brand-name only medication with no generic form currently available. Patients get it through a pharmacy with a valid prescription, and the prescribing doctor determines the treatment plan.
How Does Xiidra Work?
Xiidra works by blocking LFA-1 proteins on immune T-cells, preventing them from binding to the eye surface and releasing inflammatory chemicals called cytokines that drive chronic dry eye disease. This targeted approach interrupts the inflammatory cycle rather than masking symptoms.
And here’s the best part: unlike artificial tears, which only add surface moisture, Xiidra targets the underlying inflammation that damages tear-producing glands. The result is longer-lasting relief without constant reapplication throughout the day.
What Is the LFA-1 Mechanism in Xiidra?
LFA-1 is a protein found on the surface of T-cells that, in dry eye disease, allows immune cells to bind to the eye surface and release cytokines that damage tear-producing glands. It’s the specific target that lifitegrast blocks.
Think of it this way: lifitegrast attaches to the LFA-1 protein, stopping T-cells from docking on the eye surface. The molecular block prevents the release of inflammatory cytokines, breaking the self-perpetuating cycle of chronic eye surface damage.
How Does Xiidra Reduce Inflammation?
Xiidra reduces inflammation by blocking LFA-1, stopping T-cells from activating and releasing inflammatory substances that cause irritation, redness, and damage to tear glands and the eye surface. The process directly disrupts the immune cascade driving dry eye.
So what does that mean for patients? By reducing inflammation, Xiidra allows the tear film to stabilize, which decreases dryness and discomfort and improves tear quality over time. A healthier tear film means fewer symptoms with continued use.
According to the TFOS DEWS II Management and Therapy Report, lifitegrast has been shown in clinical trials to improve both signs and symptoms of dry eye disease, including improved inferior corneal staining at 12 weeks in 3 of 4 studies.
What Are the Ingredients in Xiidra?
Xiidra contains lifitegrast at 5% concentration (50 mg per mL), formulated as an ophthalmic solution classified as an LFA-1 antagonist and approved for prescription use in dry eye disease. That’s the only available strength for this medication.
Key inactive ingredients include sodium chloride, sodium phosphate dibasic anhydrous, and water for injection. The solution is colorless to slightly brownish-yellow with a pH range of 7.0 to 8.0, formulated for ocular compatibility.
To be clear: Xiidra is preservative-free, which reduces additional irritation on the already-sensitive ocular surface. The single-use vial format ensures sterility with each dose, eliminating the preservative-related irritation common with multi-dose bottles.
Xiidra Formulation Details:
| Component | Detail |
| Active Ingredient | Lifitegrast 5% (50 mg/mL) |
| Drug Class | LFA-1 Antagonist |
| Formulation | Sterile ophthalmic solution |
| Preservative Status | Preservative-free |
| pH Range | 7.0 to 8.0 |
| Volume Per Vial | 0.2 mL single-use |
What Are the Benefits of Xiidra?
Xiidra reduces both dry eye symptoms (what patients feel) and signs (what doctors can see), including relief from burning, itching, redness, and irritation that interfere with daily activities like reading and computer use. The dual benefit is clinically verified.
In fact, unlike over-the-counter artificial tears that only provide temporary lubrication, Xiidra addresses the root cause of inflammation and provides sustained relief. It’s particularly valuable for patients with contact lens intolerance caused by dry eye.
Does Xiidra Actually Relieve Dry Eye Symptoms?
Yes. Xiidra reduced symptoms of eye dryness at 2 weeks in 2 of 4 clinical trials, and at 6 and 12 weeks in all 4 clinical studies comparing lifitegrast 5% to vehicle. The evidence spans multiple independent trials.
And the real-world data backs it up. A survey of eye care practitioners found that 67% reported their patients had near or complete symptom resolution after 1 to 3 months of lifitegrast treatment. The average satisfaction rating for effectiveness was 6.6 out of 10 on a Likert scale.
In a post-marketing study, contact lens wearers taking Xiidra experienced a decrease in end-of-day eye discomfort and dryness, with an increase in comfortable lens wear time as early as 2 weeks into treatment.
How Long Does It Take Xiidra to Work?
Xiidra may begin reducing dry eye symptoms as early as two weeks, though full benefits are typically observed at 6 to 12 weeks of consistent twice-daily use. Individual timelines vary based on the severity of the underlying inflammation.
Here’s the reality: many patients report meaningful improvement in dryness, grittiness, and burning within the first 2 to 6 weeks, particularly when they maintain the twice-daily dosing schedule. Skipping doses extends the time needed to see results.
What Do Xiidra Reviews Say?
Xiidra has an average rating of 4.3 out of 10 from 457 total reviews on Drugs.com, with 26% of reviewers reporting a positive experience and 52% reporting a negative experience. Patient responses vary considerably based on individual factors.
On WebMD, Xiidra has an average rating of 2.4 out of 5 from 95 reviews, with approximately 27% of reviewers reporting a positive effect. The reviews reflect the reality that dry eye medications work differently for different patients.
Xiidra Ratings Across Platforms:
| Platform | Rating | Reviews | Positive |
| Drugs.com | 4.3 / 10 | 457 | 26% |
| WebMD | 2.4 / 5 | 95 | 27% |
| Sermo (Physicians) | 97% satisfaction | N/A | 97% |
What Do Positive Xiidra Reviews Say?
Positive Xiidra reviewers describe significant improvement in eye comfort, reduced redness, and the ability to wear contact lenses for longer periods, with one patient of 20+ years of dry eye reporting very positive results and stopping use of redness-reducing drops entirely.
And the contact lens stories stand out. Several positive reviewers specifically mention improved contact lens tolerance. One patient reported managing only about 2 hours of lens wear in dry environments before needing to remove them. Xiidra changed that outcome.
What Are the Common Complaints About Xiidra?
The most frequently reported complaints include burning and stinging upon application, a persistent bad taste (dysgeusia), blurry vision after application, and eye puffiness with prolonged use. These effects are consistent across multiple negative reviewers.
Here’s what no one tells patients upfront: some users report worsening vision with prolonged use. One reviewer noted needing a stronger prescription for contacts after 2 years of Xiidra use, and developed significant eye puffiness. The reviewer spent $500 on fillers before realizing Xiidra was the cause.
Cost is another recurring issue. Some patients report copays of $200 per prescription without adequate insurance coverage. That makes consistent long-term use financially difficult for many.
What Are the Side Effects of Xiidra?
The most common side effects of Xiidra occur in 5-25% of patients and include instillation site irritation, dysgeusia (altered taste sensation), and reduced visual acuity, according to FDA labeling from clinical trials submitted in 2016.
Less than 5% of patients report conjunctival hyperemia, eye discharge, itchy eyes, and sinusitis. Headache and watery eyes are also possible but occur in a smaller subset of users.
Rare but serious reactions include allergic hypersensitivity responses involving eye swelling and skin rash around the eyes. Patients must seek immediate medical care if symptoms of an allergic reaction appear after using Xiidra.
Xiidra Side Effects by Frequency:
| Side Effect | Frequency | Severity |
| Instillation site irritation | 5-25% of patients | Mild, temporary |
| Dysgeusia (bad taste) | 5-25% of patients | Mild, manageable |
| Reduced visual acuity | 5-25% of patients | Mild, temporary |
| Conjunctival hyperemia | Less than 5% | Mild |
| Eye discharge | Less than 5% | Mild |
| Allergic reaction | Rare | Serious, seek care |
Why Does Xiidra Cause a Bad Taste?
The metallic, bitter, or salty taste from Xiidra occurs because eye drops drain through the tear ducts into the nasolacrimal duct and down the back of the throat, which is a normal part of how the eye drainage system functions. The taste is not a sign that anything went wrong.
Good news? Many patients manage it by applying Xiidra immediately before brushing their teeth. While the taste is described as unpleasant by most users, the majority consider it manageable once they develop a routine around it.
Is Eye Irritation from Xiidra Normal?
Yes. A brief burning or stinging sensation is the single most common complaint with Xiidra; dry eye patients already have an irritated ocular surface, so any liquid can trigger a brief sting upon application. The reaction is expected and temporary.
These side effects typically improve within a few minutes after application. They’re also more noticeable when first starting Xiidra and generally improve as dry eye symptoms improve after 6 to 12 weeks of consistent use.
Xiidra vs Restasis: Which Is Better?
Xiidra and Restasis work through different inflammatory pathways; Xiidra is an LFA-1 antagonist while Restasis is a calcineurin inhibitor (cyclosporine 0.05%), meaning they target different parts of the immune-mediated dry eye process. Neither is universally superior.
Here’s why the timing difference matters: Xiidra showed symptom improvement as early as 2 weeks for some patients in clinical studies, while Restasis clinical trials demonstrated improvements primarily at 6 months with consistent use.
Restasis most common side effect is ocular burning in 17% of patients, while Xiidra’s most distinctive side effect is dysgeusia (bad taste). Individual responses vary, and some patients use both medications under an eye doctor’s guidance for maximum benefit.
Xiidra vs Restasis Comparison:
| Factor | Xiidra | Restasis |
| Active Ingredient | Lifitegrast 5% | Cyclosporine 0.05% |
| Drug Class | LFA-1 Antagonist | Calcineurin Inhibitor |
| Onset of Action | Some patients: 2 weeks | Primarily at 6 months |
| Common Side Effect | Bad taste (dysgeusia) | Ocular burning (17%) |
| Preservative-Free | Yes | No (emulsion) |
How Much Does Xiidra Cost?
Xiidra is available only as a brand-name medication with no generic form available. This status makes it one of the more expensive dry eye treatments; some patients report out-of-pocket copays of $200 per prescription without adequate insurance coverage.
But here’s the good news: Bausch + Lomb offers the Xiidra Savings Card, which allows eligible patients to pay as little as $0 per prescription. This offer isn’t valid for patients whose prescriptions are reimbursed by federal programs like Medicaid or Medicare.
Is Xiidra Covered by Insurance?
Xiidra has the best insurance coverage among any branded dry eye prescription product across commercial and Medicare prescription plans, according to Bausch + Lomb. Coverage is broader than most competing brand-name dry eye drops.
That said, coverage still varies by individual plan. Patients should check with their insurer and eye doctor about formulary placement. Savings card programs are available for commercially insured patients to further reduce out-of-pocket costs.
Is Xiidra Safe?
Xiidra received FDA approval in July 2016 specifically for treating both the signs and symptoms of dry eye disease; it’s classified as a nonsteroid anti-inflammatory prescription medication and is not considered an immunosuppressant.
Xiidra isn’t approved for children under 17 years. Patients allergic to lifitegrast or any ingredient in Xiidra should not use it, and should seek immediate medical care if symptoms of an allergic reaction develop.
The American Academy of Ophthalmology notes that Xiidra has been shown effective over 3 months. However, the safety and efficacy of use beyond 12 months isn’t yet fully established, making ongoing conversations with an eye doctor important.
Who Should Not Use Xiidra:
- Patients allergic to lifitegrast or any Xiidra ingredient
- Children under 17 years of age
- Patients experiencing worsening symptoms or severe reactions
- Anyone without a valid prescription from a licensed eye doctor
How to Use Xiidra Eye Drops?
The recommended dose of Xiidra is one drop in each eye twice daily, approximately 12 hours apart; each monthly supply includes 60 single-use vials — 2 vials per day for both morning and evening doses. Consistent timing supports steady medication levels on the eye surface.
Remove contact lenses before applying Xiidra and wait at least 15 minutes before reinserting them. Don’t touch the container tip to the eye or any surface to avoid contamination of the sterile solution.
Store Xiidra at room temperature between 68 degrees F and 77 degrees F (20 degrees C and 25 degrees C) in the original foil pouch to protect from light. Each vial is for single use only and must be discarded after treating both eyes, even if solution remains.
Xiidra Application Steps:
- Wash hands thoroughly before handling the vial.
- Remove contact lenses if applicable.
- Twist off the tab to open a single-use vial.
- Tilt head back and pull down the lower eyelid to form a pouch.
- Squeeze one drop into the pouch without touching the tip to the eye.
- Close the eye gently to spread the drops.
- Repeat for the second eye using the same vial.
- Discard the vial with any remaining solution.
- Wait 15 minutes before reinserting contact lenses.
Is Xiidra Worth It?
Xiidra is particularly worth considering for patients with moderate to severe inflammatory dry eye who haven’t responded to artificial tears; its FDA approval, unique LFA-1 mechanism, and multi-trial clinical evidence support its use as a first-line prescription option.
Patients whose dry eye symptoms interfere with reading, computer use, driving, or contact lens wear gain the most benefit from Xiidra. Those who didn’t respond to cyclosporine-based drops also report success because of Xiidra’s different mechanism.
Mixed patient reviews (4.3 out of 10 on Drugs.com) suggest results vary widely. Cost without insurance assistance, the taste side effect, and the need for consistent twice-daily use are factors worth discussing with an eye doctor before starting treatment.